atai Life Sciences Announces Results from the Kures Therapeutics Phase 1 Trial of KUR-101
Posted:
atai Life Sciences, a clinical stage biopharmaceutical company aiming to transform the treatment of mental health disorders, announced additional clinical data from the Kures Therapeutics Phase 1 trial of KUR-101 in healthy volunteers. This two-part trial was designed to assess the safety, tolerability, pharmacokinetics, and analgesic activity of KUR-101. Read more here.
Operating System Leverage in Electronic Records, or O.S.L.E.R., is a fully digital AI staff member, an AI agent that can see the screen and use the mouse and keyboard just like you do.
If you want to find out more about…
Discovery Park have secured a number of industry leading suppliers and experts who will be on-site to introduce you to the latest technologies and solutions for your business needs.
There will also be freebies and goodies up for grabs!
Tuesday…